ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Memantine

Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.

Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.

Drug pageMemantine: every studyMany companies study it; this page follows only the 27 they lead. All 198 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 6, 200627 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only130 open or runningphase 4since Jun 6, 2006Dec 1, 2004none ahead
H. Lundbeckits history only60 open or runningphase 4since Mar 3, 2009Mar 3, 2009none ahead
Merz Pharmaits history only40 open or runningphase 4since Mar 27, 2008Feb 14, 2008none ahead
Carnot Laboratoriesits history only10 open or runningphase 4since Feb 11, 2026Feb 11, 2026none ahead
Gedeon Richter Plc.its history only10 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Geropharm10 open or runningphase 1since Apr 18, 2017Apr 18, 2017none ahead
Mendel AIits history only10 open or runningphase 3since Jan 30, 2021Jan 30, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Geropharm only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2017First study: phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsFirst studyNCT03121820 · 18 enrolled · Russian Federation

TargetBeta

“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
EsketamineruleJohnson & Johnsonphase 451

Studies

The one study Geropharm leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03121820Bioequivalence, AUC, Cmax, Pharmacokinetics · Russian Federation1CompletedNov 19, 201618

How it is read

Names in the registry

  • “Memantine”, 11 entries
  • “Memantine Hydrochloride (HCl)”, 4 entries
  • “memantine”, 3 entries
  • “memantine HCl”, 3 entries
  • “Memantine HCl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.